Popular topics to explore
🚀 50 Stocks With Strong Q1 FY27 Concall Commentary 📊🔥
🔹 #SGMART — 🚀 118% EBITDA growth outlook; ₹300 Cr EBITDA target for FY27 🔹 #SENORES — 💊 Targeting 30–40% revenue growth and 50–60% PAT growth in FY27 🔹 #SAKAR — 🧬 25% revenue CAGR with 50%+ PAT growth; oncology business ramp-up is a…
Stocks With Strong Future Guidance — Worth Tracking
• V-Marc
• RR Kabel
• Finolex
• HFCL HFCL
• E2E Networks
• MTAR Technologies
• Syrma SGS
• Netweb Technologies
• Sterlite Technologies
• Sansera Engineering
• Azad Engineering
• Omnitech Engineering
• Dynamatic Technologies
• Aequs
• Ross…
🚀 50 Stocks With Strong Q1 FY27 Concall Commentary 📊🔥
🚀 50 Stocks With Strong Q1 FY27 Concall Commentary 📊🔥
!SGMART SBCL
🔹 #SGMART — 🚀 118% EBITDA growth outlook; ₹300 Cr EBITDA target for FY27
🔹 #SENORES — 💊 Targeting 30–40% revenue growth and 50–60% PAT growth in FY27
🔹 #SAKAR…
High-Growth Small-Cap Stocks to Track for the Next Few Years
High-Growth Small-Cap Stocks to Track for the Next Few Years
Small-Cap Growth Watchlist MTARTECH
1. E2E Networks
2. MTAR Technologies
3. Syrma SGS Technology
5. HFCL
6. Deep Industries
7. Apcotex Industries
8. Fineotex Chemical
9. Beta…
Sakar Healthcare Ltd operates within pharmaceutical manufacturing and contract development and manufacturing (CDMO)
SAKAR
Focusing on injectable formulations, sterile products, and value-added pharmaceutical solutions. The bullish thesis is driven by structural outsourcing in global pharma, where innovator companies increasingly depend on cost-efficie…
22nd Feb · SEBI-Registered Analyst
Investment Insights with Adarsh · 22nd Feb
Sakar Healthcare Ltd – Stock Overview
SAKAR
Company Profile
Sakar Healthcare Ltd is an Indian pharmaceutical company engaged in manufacturing injectable medicines, oral liquids, syrups and nutraceutical products. The company supplies pharmaceutical formulations to domestic as…
Sakar Healthcare — Trendline Reclaim With Volume Expansion & Momentum Strength
SAKAR
1️⃣ Price Structure & Trendlines:
Price has reclaimed the broader falling trendline and is now moving within a rising structure. The recent impulsive candle suggests transition from corrective behaviour toward potential continuation…
SWOT ANALYSIS – Sakar Healthcare Ltd
SAKAR
Strengths
Revenue Growth Momentum: The company reported solid revenue increases (e.g., ~28% YoY growth in a recent quarter), indicating strong market traction.
Diversified Product Portfolio: Operates across multiple therapeutic c…
Sakar Foodworld Ltd – SWOT Analysis
SAKAR
Strengths
Quick Service Restaurant (QSR) Presence: Operates in the growing Indian fast-food and casual dining space.
Local Brand Focus: Ability to tailor menu offerings to regional tastes and price sensitivity.
Asset-Light Expans…
SAKAR HEALTHCARE:
Q3 SL NET PROFIT 102M RUPEES VS 45M (YOY)
SAKAR HEALTHCARE: Q3 EBITDA 186M RUPEES VS 118M (YOY) || Q3 EBITDA MARGIN 26.4% VS 27.1% (YOY)
SAKAR
20th Jun 2025 · SEBI-Registered Analyst
Trade with Shubham Shirkar · 20th Jun 2025
💊 Earning Without Owning — Welcure’s ₹517 Cr Deal Shows a New Asset-Light Playbook 📦💼
Imagine earning ₹26 crore next year without running a factory or buying any stock. Sounds unreal? That’s what Welcure Drugs & Pharmaceuticals Ltd. just pulled off. They’ve signed a ₹517 crore sourcing agreement with Thailand-based Fortun…
